The unquestioned leader in a virtual care sector that has surged in the Covid-19 era, Teladoc has a relationship with more than one-fifth of the U.S. population. The telemedicine provider’s planned acquisition of diabetes coaching company Livongo is poised to make it even more of a juggernaut: The two companies had a combined market capitalization of nearly $30 billion as of the end of the day on Monday.

But Teladoc’s dominance was not inevitable. In interviews with STAT, Teladoc’s founders, early employees, and industry analysts pointed to the many successful bets the company placed over the years — long before it was clear how best to build a telemedicine business, or whether one could even take off. Among them: the company’s early launch and early IPO, its decision to sell only a deluxe product at a deluxe price, and its focus on complementing — rather than replacing — the existing health care system.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy